Artime, Esther http://orcid.org/0000-0003-4294-6462
Qizilbash, Nawab
Herruzo, Rafael
Garrido-Estepa, Macarena
Article History
Accepted: 1 October 2020
First Online: 3 November 2020
Declarations
:
: No funding was received for the preparation of this article.
: Nawab Qizilbash is an employee of OXON Epidemiology, a scientific service provider to the pharmaceutical industry that conducts PASS risk minimisation studies sponsored by companies. Esther Artime is an employee of Lilly Spain; however, this work was carried out as part of her doctoral thesis at Universidad Autónoma de Madrid, and therefore is not linked to her current work at Lilly. Rafael Herruzo and Macarena Garrido-Estepa have no conflicts of interest that are directly related to the content of this article.
: As this study was a review of existing literature, no ethical approval was required.
: Not applicable.
: Not applicable.
: All data were extracted from existing study reports and publications that can be accessed on-line.
: Not applicable.
: EA, M-GE and NQ contributed to the conception and design of the article. The systematic search, data extraction and analysis were performed by EA and M-GE. The first draft of the manuscript was written by EA and all authors critically revised the work. All authors read and approved the final manuscript.